Arenas-León, José L.
Morales-Villegas, Enrique C.
Cardona-Muñoz, Ernesto G.
Alcocer-Gamba, Marco A.
Ramirez-Contreras, Juan P.
Contreras-Sandoval, Aleida Y.
González-Galvez, Guillermo http://orcid.org/0000-0001-9611-2055
Funding for this research was provided by:
Novonordisk
Article History
Received: 23 August 2023
Accepted: 24 November 2023
First Online: 7 December 2023
Declarations
:
: <b>“</b>The study in Mexico was approved by the regulatory authorities (Cofepris) and the research and ethics committee of each participating center. All participants provided written informed consent prior to inclusion. A total of 32 sites (6 specialized diabetes treatment centers and 26 primary care centers) distributed all around Mexico with 91 investigators and assistant investigators participated in the study. Patients were recruited from December 2018 to September 2019.”
: José L. Arenas-León; Enrique C. Morales-Villegas; Ernesto G. Cardona-Muñoz; Marco A. Alcocer-Gamba; Juan P. Ramirez-Contreras; Aleida Y. Contreras-Sandoval; Guillermo González-Galvez give their full consent for publication.
: José L. Arenas-León ; Enrique C. Morales-Villegas; Ernesto G. Cardona-Muñoz; Marco A. Alcocer-Gamba and Guillermo González-Galvez have not competing interests for this publication. Juan P. Ramirez-Contreras and Aleida Y. Contreras-Sandoval are employees of Novonordisk.